TY - JOUR
T1 - Efficacy and Safety of Low-Molecular-Weight Heparin on Prevention of Venous Thromboembolism after Laparoscopic Operation for Gastrointestinal Malignancy in Japanese Patients
T2 - A Multicenter, Open-Label, Prospective, Randomized Controlled Trial
AU - Tohoku Surgical Clinical Research Promotion Organization Study Group
AU - Obitsu, Tamotsu
AU - Tanaka, Naoki
AU - Oyama, Atsushi
AU - Ueno, Tatsuya
AU - Saito, Masaaki
AU - Yamaguchi, Takuhiro
AU - Takagi, Airi
AU - Rikiyama, Toshiki
AU - Unno, Michiaki
AU - Naitoh, Takeshi
AU - Shimamura, Hiromune
AU - Suto, Takeshi
AU - Saijo, Fumito
AU - Yamauchi, Junichiro
AU - Miura, Koh
N1 - Funding Information:
Disclosures outside the scope of this work: Dr Rikiyama’s institute receives grant funding from Arai Hospital, Kyosai Hospital, Nerima Hikarigaoka Hospital, Oomiya Chuo Hospital, Uwamachi Hospital, Taiho Yakuhin Kogyo, Kaken Seiyaku, Otsuka Seiyaku Kogyo, Chugai Seiyaku, Yakult Honsha, Sanofi, Daiichisankyo, Covidien Japan, Lilly Japan, Asahikasei Medical, Takeda Yakuhin Kogyo, Nihon Kayaku, Asahikasei Pharma, Merck Serono, Kyowakirin, and Eisai. Dr Rikiyama receives lecture payments from Taiho Yakuhin Kogyo, Takeda Yakuhin Kogyo, Chugai Seiyaku, Ono Yakuhin Kogyo, Asahikasei Pharma, Covidien Japan, Eisai, Yakult Honsha, Lilly Japan, Miyarisan, Teijin Pharma, Alfresa Pharma, Johnson & Johnson, Kaken Seiyaku, Kowa Souyaku, Novartis Japan, Bayer Yakuhin, Nihon Kayaku, Astellas Seiyaku, and Daiichisankyo. Drs Tanaka and Unno receive lecture payments from Johnson & Johnson, Inc; Medtronic Japan, Inc; and Olympus Medical Science Sales Corporation. Dr Unno’s institute receives grant funding from Taiho Pharm, Takeda Pharm, Chugai Pharm, Asahi−Kasei, Yakult Honsha, and MSD. Dr Unno receives lecture payments from Taiho Pharm. Dr Naitoh receives lecture payments from TERUMO, Sumitomo Bakelite, Takeda Pharm, Chugai Pharm, Merck, and MC Medical. All other authors have nothing to disclose.
Funding Information:
Support: This study was supported by a grant from Tohoku Surgical Clinical Research Promotion Organization study group NEXTSURG for data collection. Drs Tanaka and Naitoh’s institute receives grants from the Japan Society for the Promotion of Science (Grant-in-Aid for Scientific Research [C] [#17K10575]). Dr Tanaka’s institute receives grant funding from the Japan Society for the Promotion of Science (Grant-in-Aid for Scientific Research [C] [20K09066]), and the Gonryo Medical Scholarship Promotion Association (Anzai Memorial Prize for Diabetes Research). Dr Unno’s institute receives grant funding from the Japan Society for the Promotion of Science (Grant-in-Aid for Scientific Research).
Publisher Copyright:
© 2020 American College of Surgeons
PY - 2020/11
Y1 - 2020/11
N2 - Background: The risk of venous thromboembolism (VTE) after surgery for malignancy in Japanese patients is unclear; therefore, standard prevention protocols have not been established, especially for minimally invasive procedures. We aimed to investigate the additional effect of low molecular weight heparin (LMWH) on prevention of VTE after laparoscopic surgery for gastrointestinal malignancy. Study Design: From February 2013 to January 2017, 400 patients scheduled for laparoscopic surgery were included. Cases were randomly allocated to the physical therapy group (Control group; 201 patients) or to the combination-therapy group (LMWH group; 199 patients), in which enoxaparin sodium (20 mg [= 2000 IU] twice a day) was administered for 1 week postoperatively in addition to the physical therapy. A diagnosis of VTE was made by contrast-enhanced CT or ultrasonography when symptomatic or D-dimer was ≥10 μg/mL. Results: VTE was observed in 1.2% and 4.0% of patients in the LMWH and Control groups, respectively (odds ratio [OR] 0.3, 95% confidence interval [CI] 0.03–1.53). Pulmonary embolism was confirmed only in the Control group (1.7%). No major bleeding occurred in either group. Logistic multiple regression analysis revealed that surgical time extension (OR 1.02, 95% CI 1.00–1.04) was a risk factor of VTE, while administration of LMWH (OR 0.21, 95% CI 0.03–0.99), male sex (OR 0.12, 95% CI 0.01–0.60), and early cancer (OR 0.17, 95% CI 0.02–0.82) reduced the risk of VTE. Conclusions: Postoperative LMWH administration is safe. The additional effect of LMWH administration on the physical therapy was not statistically proven in this study. However, it could be useful for the patients with risk factors such as female sex, long operation time, and higher cancer stage.
AB - Background: The risk of venous thromboembolism (VTE) after surgery for malignancy in Japanese patients is unclear; therefore, standard prevention protocols have not been established, especially for minimally invasive procedures. We aimed to investigate the additional effect of low molecular weight heparin (LMWH) on prevention of VTE after laparoscopic surgery for gastrointestinal malignancy. Study Design: From February 2013 to January 2017, 400 patients scheduled for laparoscopic surgery were included. Cases were randomly allocated to the physical therapy group (Control group; 201 patients) or to the combination-therapy group (LMWH group; 199 patients), in which enoxaparin sodium (20 mg [= 2000 IU] twice a day) was administered for 1 week postoperatively in addition to the physical therapy. A diagnosis of VTE was made by contrast-enhanced CT or ultrasonography when symptomatic or D-dimer was ≥10 μg/mL. Results: VTE was observed in 1.2% and 4.0% of patients in the LMWH and Control groups, respectively (odds ratio [OR] 0.3, 95% confidence interval [CI] 0.03–1.53). Pulmonary embolism was confirmed only in the Control group (1.7%). No major bleeding occurred in either group. Logistic multiple regression analysis revealed that surgical time extension (OR 1.02, 95% CI 1.00–1.04) was a risk factor of VTE, while administration of LMWH (OR 0.21, 95% CI 0.03–0.99), male sex (OR 0.12, 95% CI 0.01–0.60), and early cancer (OR 0.17, 95% CI 0.02–0.82) reduced the risk of VTE. Conclusions: Postoperative LMWH administration is safe. The additional effect of LMWH administration on the physical therapy was not statistically proven in this study. However, it could be useful for the patients with risk factors such as female sex, long operation time, and higher cancer stage.
UR - http://www.scopus.com/inward/record.url?scp=85090596507&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85090596507&partnerID=8YFLogxK
U2 - 10.1016/j.jamcollsurg.2020.08.734
DO - 10.1016/j.jamcollsurg.2020.08.734
M3 - Article
C2 - 32822887
AN - SCOPUS:85090596507
SN - 1072-7515
VL - 231
SP - 501-509.e2
JO - Journal of the American College of Surgeons
JF - Journal of the American College of Surgeons
IS - 5
ER -